TR200302242T2 - Protein kinaz önleyicileri olarak pirolopirimidinler - Google Patents

Protein kinaz önleyicileri olarak pirolopirimidinler

Info

Publication number
TR200302242T2
TR200302242T2 TR2003/02242T TR200302242T TR200302242T2 TR 200302242 T2 TR200302242 T2 TR 200302242T2 TR 2003/02242 T TR2003/02242 T TR 2003/02242T TR 200302242 T TR200302242 T TR 200302242T TR 200302242 T2 TR200302242 T2 TR 200302242T2
Authority
TR
Turkey
Prior art keywords
pyrolopyrimidines
protein kinase
kinase inhibitors
prodrugs
oxides
Prior art date
Application number
TR2003/02242T
Other languages
English (en)
Turkish (tr)
Inventor
Paul Cox Joseph
Tahir Majid Nadeem
Amendola Shelly
Stephanie Deprets Daniele
Edlin Chris
Brian Pedgrift Leslie
Halley Frank
Wards Michael
Baudion Bernard
Lain Mclay Mcfarlane
John Aldous David
Original Assignee
Aventis Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc. filed Critical Aventis Pharmaceuticals Inc.
Publication of TR200302242T2 publication Critical patent/TR200302242T2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TR2003/02242T 2001-06-23 2002-06-21 Protein kinaz önleyicileri olarak pirolopirimidinler TR200302242T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0115393.1A GB0115393D0 (en) 2001-06-23 2001-06-23 Chemical compounds
US30167801P 2001-06-28 2001-06-28

Publications (1)

Publication Number Publication Date
TR200302242T2 true TR200302242T2 (tr) 2004-12-21

Family

ID=9917225

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2003/02242T TR200302242T2 (tr) 2001-06-23 2002-06-21 Protein kinaz önleyicileri olarak pirolopirimidinler

Country Status (22)

Country Link
EP (1) EP1404676A1 (https=)
JP (1) JP4344607B2 (https=)
CN (1) CN1294135C (https=)
AU (1) AU2002314325B8 (https=)
BR (1) BR0210652A (https=)
CA (1) CA2451932C (https=)
CZ (1) CZ20033443A3 (https=)
EA (1) EA007415B1 (https=)
EC (1) ECSP034922A (https=)
EE (1) EE05432B1 (https=)
GB (1) GB0115393D0 (https=)
HU (1) HUP0400300A3 (https=)
ME (1) MEP19308A (https=)
NZ (1) NZ529766A (https=)
OA (1) OA12632A (https=)
PL (1) PL374096A1 (https=)
RS (1) RS51698B (https=)
SK (1) SK15882003A3 (https=)
TN (1) TNSN03144A1 (https=)
TR (1) TR200302242T2 (https=)
UA (1) UA76760C2 (https=)
WO (1) WO2003000695A1 (https=)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0202679D0 (en) * 2002-02-05 2002-03-20 Glaxo Group Ltd Novel compounds
HRP20050089B1 (hr) 2002-07-29 2015-06-19 Rigel Pharmaceuticals Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti
WO2005012294A1 (en) 2003-07-30 2005-02-10 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
CA2546192C (en) 2003-11-17 2010-04-06 Pfizer Products Inc. Pyrrolopyrimidine compounds useful in treatment of cancer
EP1689407A1 (en) * 2003-11-25 2006-08-16 Pfizer Products Inc. Method of treatment of atherosclerosis
US20050250829A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Kinase inhibitors
WO2006023931A2 (en) 2004-08-18 2006-03-02 Takeda San Diego, Inc. Kinase inhibitors
FR2876103B1 (fr) 2004-10-01 2008-02-22 Aventis Pharma Sa Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
FR2878849B1 (fr) 2004-12-06 2008-09-12 Aventis Pharma Sa Indoles substitues, compositions les contenant, procede de fabrication et utilisation
JP2008543855A (ja) 2005-06-13 2008-12-04 ライジェル ファーマシューティカルズ， インコーポレイテッド 変形性骨疾患を処置するための方法および組成物
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
KR20150036210A (ko) 2007-06-13 2015-04-07 인사이트 코포레이션 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염
EP2247596A2 (en) 2008-01-11 2010-11-10 Natco Pharma Limited Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents
CN104592231A (zh) 2008-06-10 2015-05-06 Abbvie公司 新的三环化合物
SI2432472T1 (sl) 2009-05-22 2019-11-29 Incyte Holdings Corp 3-(4-(7H-pirolo(2,3-d)pirimidin-4-il)-1H-pirazol-1-il)oktan- ali heptan-nitril kot inhibitorji JAK
AR076794A1 (es) 2009-05-22 2011-07-06 Incyte Corp Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
WO2011018894A1 (en) * 2009-08-10 2011-02-17 Raqualia Pharma Inc. Pyrrolopyrimidine derivatives as potassium channel modulators
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP2485589A4 (en) 2009-09-04 2013-02-06 Biogen Idec Inc HETEROARYL-BTK INHIBITORS
RU2711869C3 (ru) 2009-12-01 2022-02-02 Эббви Инк. Имидазопирролопиразиновые производные, полезные для лечения заболеваний, вызванных аномальной активностью протеинкиназ Jak1, Jak3 или Syk
EP3354652B1 (en) 2010-03-10 2020-05-06 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
PE20130216A1 (es) 2010-05-21 2013-02-27 Incyte Corp Formulacion topica para un inhibidor de jak
PE20140146A1 (es) 2010-11-19 2014-02-06 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
CN103476776B (zh) * 2011-01-07 2016-09-28 北京赛林泰医药技术有限公司 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物
CN102093364B (zh) * 2011-01-07 2015-01-28 北京赛林泰医药技术有限公司 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物
CN103797010B (zh) 2011-06-20 2016-02-24 因塞特控股公司 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
JP6182593B2 (ja) 2012-04-20 2017-08-16 アドヴィーナス セラピューティクス リミテッド 置換ヘテロ二環化合物、組成物及び医薬並びにそれらの用途
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
KR101916443B1 (ko) 2012-07-26 2018-11-08 글락소 그룹 리미티드 Pad4 억제제로서의 2-(아자인돌-2-일) 벤즈이미다졸
EP2892534B8 (en) * 2012-09-06 2021-09-15 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
PH12020551186B1 (en) 2012-11-15 2024-03-20 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
RS62867B1 (sr) 2013-03-06 2022-02-28 Incyte Holdings Corp Postupci i intermedijeri za dobijanje inhibitora jak
WO2014159999A1 (en) 2013-03-13 2014-10-02 Abbvie Inc. Cdk9 kinase inhibitors
EP2970200A1 (en) 2013-03-13 2016-01-20 Abbvie Inc. Pyridine cdk9 kinase inhibitors
WO2014151444A1 (en) 2013-03-14 2014-09-25 Abbvie Inc. Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors
US9796708B2 (en) 2013-03-14 2017-10-24 Abbvie Inc. Pyrrolo [2,3-B] pyridine CDK9 kinase inhibitors
AU2014244194A1 (en) 2013-03-14 2015-09-10 Abbvie Inc. Pyrrolopyrimindine CDK9 kinase inhibitors
SMT202000315T1 (it) 2013-08-07 2020-07-08 Incyte Corp Forme di dosaggio a rilascio prolungato per un inibitore di jak1
CN104804001B9 (zh) * 2014-01-24 2022-02-08 江苏柯菲平医药股份有限公司 4-取代吡咯并[2,3-d]嘧啶化合物及其用途
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
SG10201913990RA (en) 2015-10-16 2020-03-30 Abbvie Inc PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
AU2018230500B2 (en) 2017-03-09 2024-03-07 Abbvie Inc. Methods of treating Crohn's disease and ulcerative colitis
US11564922B2 (en) 2017-03-09 2023-01-31 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
SG11202007164UA (en) 2018-01-30 2020-08-28 Incyte Corp Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
SMT202400306T1 (it) 2018-03-30 2024-09-16 Incyte Corp Trattamento dell'idrosadenite suppurativa utilizzando inibitori di jak.
MX2021003904A (es) 2018-10-05 2021-10-26 Annapurna Bio Inc Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor apj.
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1441497A (en) * 1996-01-23 1997-08-20 Novartis Ag Pyrrolopyrimidines and processes for their preparation
WO1998023613A1 (en) * 1996-11-27 1998-06-04 Pfizer Inc. Fused bicyclic pyrimidine derivatives
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
SK286640B6 (sk) * 1998-06-19 2009-03-05 Pfizer Products Inc. Pyrol [2,3-d] pyrimidínová zlúčenina, jej použitie na výrobu liečiva, farmaceutická kompozícia s jej obsahom, použitie jej kombinácie s ďalšími činidlami a súpravy s jej obsahom na výrobu liečiva
ES2253930T3 (es) * 1998-09-18 2006-06-01 ABBOTT GMBH & CO. KG 4-aminopirrolopirimidinas como inhibidores de quinasa.
DE60037345T2 (de) * 1999-12-10 2008-11-13 Pfizer Products Inc., Groton Pyrrolo(2,3-d)pyrimidin-Verbindungen

Also Published As

Publication number Publication date
CA2451932C (en) 2009-12-29
AU2002314325B2 (en) 2009-01-08
JP4344607B2 (ja) 2009-10-14
BR0210652A (pt) 2004-08-10
OA12632A (en) 2006-06-14
NZ529766A (en) 2008-11-28
WO2003000695A1 (en) 2003-01-03
SK15882003A3 (sk) 2004-07-07
EA200400073A1 (ru) 2004-08-26
UA76760C2 (uk) 2006-09-15
HUP0400300A3 (en) 2010-12-28
CN1294135C (zh) 2007-01-10
EA007415B1 (ru) 2006-10-27
EP1404676A1 (en) 2004-04-07
CZ20033443A3 (en) 2004-03-17
GB0115393D0 (en) 2001-08-15
EE200400003A (et) 2004-02-16
PL374096A1 (en) 2005-09-19
RS99203A (sr) 2006-12-15
HUP0400300A2 (en) 2007-08-28
EE05432B1 (et) 2011-06-15
ECSP034922A (es) 2004-04-28
TNSN03144A1 (en) 2005-12-23
WO2003000695A8 (en) 2004-03-11
CA2451932A1 (en) 2003-01-03
CN1518552A (zh) 2004-08-04
MEP19308A (en) 2010-06-10
JP2005508300A (ja) 2005-03-31
RS51698B (sr) 2011-10-31
AU2002314325B8 (en) 2009-01-29

Similar Documents

Publication Publication Date Title
TR200302242T2 (tr) Protein kinaz önleyicileri olarak pirolopirimidinler
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
AP2003002929A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
TR200103186T2 (tr) MEK enzimlerinin inhibitörleri olarak kinolin türevleri
PL369108A1 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
TR200401029T4 (tr) Asilfenil-üre türevleri, imalat yöntemleri ve ilaç maddesi olarak kullanımları
NO20025601L (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
ATE296826T1 (de) Pyrazolo(1,5)pyridinderivate
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
MXPA04001256A (es) Productos de combinacion de derivados de propanolamina aril substituidos con otros ingredientes activos y su uso.
IS6520A (is) Ný efnasambönd
TR200201205T2 (tr) N-ikame edilmiş karbamoiloksialkil-azolyum türevleri.
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
MXPA04001328A (es) Productos en combinacion de derivados de 1,4-benzotiepina-1,1-dioxido con otros ingredientes activos, y su uso.
ATE300541T1 (de) Pyrazolopyridinderivate
DE60115466D1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
EA200301203A1 (ru) Новые соединения и композиции как ингибиторы катепсина
MXPA04003611A (es) Piperidina- y piperazinacetaminas como inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.
MXPA04005809A (es) Inhibidores de proteinas quinasas.
DE60035429D1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
ATE287886T1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer
TR200103457T2 (tr) 4-Fenil-Pirimidin Türevleri.
MXPA03008801A (es) Aril oxima-piperazinas utiles como antagonistas de ccr5.
ATE373000T1 (de) Pyrazolopyridin-derivate als antiherpesmittel